Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has earned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $20.2857.

A number of equities research analysts have recently commented on ENTA shares. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, June 23rd. Wall Street Zen cut shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC increased its position in Enanta Pharmaceuticals by 1.5% during the first quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock worth $47,717,000 after purchasing an additional 54,396 shares during the last quarter. Farallon Capital Management LLC grew its stake in shares of Enanta Pharmaceuticals by 30.6% during the 4th quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock valued at $43,719,000 after buying an additional 650,000 shares during the period. Krensavage Asset Management LLC increased its holdings in shares of Enanta Pharmaceuticals by 30.8% during the 4th quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after buying an additional 651,946 shares during the last quarter. Millennium Management LLC raised its position in shares of Enanta Pharmaceuticals by 50.2% in the 1st quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after buying an additional 449,945 shares during the period. Finally, Spruce Street Capital LP boosted its holdings in Enanta Pharmaceuticals by 139.3% in the first quarter. Spruce Street Capital LP now owns 932,598 shares of the biotechnology company’s stock valued at $11,779,000 after acquiring an additional 542,911 shares during the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Price Performance

NASDAQ ENTA opened at $13.22 on Thursday. The firm’s 50-day moving average is $13.07 and its two-hundred day moving average is $13.41. The stock has a market capitalization of $384.44 million, a P/E ratio of -5.10 and a beta of 0.98. Enanta Pharmaceuticals has a 12 month low of $6.45 and a 12 month high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.01. The business had revenue of $17.16 million during the quarter, compared to analyst estimates of $17.03 million. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. As a group, analysts anticipate that Enanta Pharmaceuticals will post -1.79 EPS for the current year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.